Literature DB >> 14999295

Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells.

M Kawakami1, T Kimura, Y Kishimoto, T Tatekawa, Y Baba, T Nishizaki, N Matsuzaki, Y Taniguchi, S Yoshihara, K Ikegame, T Shirakata, S Nishida, T Masuda, N Hosen, A Tsuboi, Y Oji, Y Oka, H Ogawa, Y Sonoda, H Sugiyama, I Kawase, T Soma.   

Abstract

Primitive hematopoietic progenitor cells such as severe combined immunodeficiency- repopulating cells and long-term culture-initiating cells are enriched in CD34+CD38- cells derived from various stem cell sources. In this study, to elucidate the features of such primitive cells at the molecular level, we tried to isolate genes that were preferentially expressed in umbilical cord blood (CB)-derived CD34+CD38- cells by subtractive hybridization. The gene for VPAC1 receptor, a receptor for the neuropeptide vasoactive intestinal peptide (VIP), was thereby isolated and it was shown that this gene was expressed in both CD34+CD38- and CD34+CD38+ CB cells and that the expression levels were higher in CD34+CD38- CB cells. Next, we assessed the effects of VIP on the proliferation of CD34+ CB cells using in vitro culture systems. In serum-free single-cell suspension culture, VIP enhanced clonal growth of CD34+ CB cells in synergy with FLT3 ligand (FL), stem cell factor (SCF), and thrombopoietin (TPO). In serum-free clonogenic assays, VIP promoted myeloid (colony-forming unit-granulocyte/macrophage (CFU-GM)) and mixed (CFU-Mix) colony formations. Furthermore, in Dexter-type long-term cultures, VIP increased colony-forming cells at week 5 of culture. These results suggest that VIP functions as a growth-promoting factor of CB-derived hematopoetic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999295     DOI: 10.1038/sj.leu.2403330

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

Authors:  Emilie E Vomhof-DeKrey; Ashley R Sandy; Jarrett J Failing; Rebecca J Hermann; Scott A Hoselton; Jane M Schuh; Abby J Weldon; Kimberly J Payne; Glenn P Dorsam
Journal:  Peptides       Date:  2011-08-22       Impact factor: 3.750

2.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

3.  EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.

Authors:  Vincent-Philippe Lavallée; Patrick Gendron; Sébastien Lemieux; Giovanni D'Angelo; Josée Hébert; Guy Sauvageau
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

4.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

5.  Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells.

Authors:  Jinxiang Yuan; Xiaoqiu Liu; Allen W Wu; Patrick W McGonagill; Michael J Keller; Courtney S Galle; Jeffery L Meier
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

6.  PACAP38/PAC1 signaling induces bone marrow-derived cells homing to ischemic brain.

Authors:  Chen-Huan Lin; Lian Chiu; Hsu-Tung Lee; Chun-Wei Chiang; Shih-Ping Liu; Yung-Hsiang Hsu; Shinn-Zong Lin; Chung Y Hsu; Chia-Hung Hsieh; Woei-Cherng Shyu
Journal:  Stem Cells       Date:  2015-04       Impact factor: 6.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.